Teleflex Incorporated (TFX) Expected to Announce Earnings of $2.40 Per Share
Brokerages expect Teleflex Incorporated (NYSE:TFX) to report $2.40 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Teleflex’s earnings. The lowest EPS estimate is $2.37 and the highest is $2.46. Teleflex posted earnings of $2.13 per share during the same quarter last year, which indicates a positive year over year growth rate of 12.7%. The firm is scheduled to report its next earnings report on Thursday, February 22nd.
On average, analysts expect that Teleflex will report full-year earnings of $8.36 per share for the current fiscal year, with EPS estimates ranging from $8.33 to $8.42. For the next year, analysts anticipate that the company will report earnings of $9.68 per share, with EPS estimates ranging from $9.60 to $9.85. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Teleflex.
Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 EPS for the quarter, beating the consensus estimate of $2.01 by $0.11. The company had revenue of $534.70 million for the quarter, compared to the consensus estimate of $522.94 million. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. The firm’s revenue was up 17.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.80 EPS.
In other news, Director George Babich, Jr. sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $283.11, for a total value of $707,775.00. Following the completion of the sale, the director now owns 9,581 shares of the company’s stock, valued at approximately $2,712,476.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $248.96, for a total transaction of $49,792.00. Following the completion of the sale, the director now directly owns 8,080 shares of the company’s stock, valued at approximately $2,011,596.80. The disclosure for this sale can be found here. Insiders sold a total of 7,600 shares of company stock worth $2,040,569 over the last 90 days. Insiders own 2.39% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in TFX. Toronto Dominion Bank lifted its position in shares of Teleflex by 14.5% in the 2nd quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 70 shares during the period. Advisory Services Network LLC lifted its position in shares of Teleflex by 933.8% in the 2nd quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock worth $172,000 after purchasing an additional 747 shares during the period. Cornerstone Capital Management Holdings LLC. purchased a new stake in Teleflex during the second quarter valued at approximately $175,000. Archford Capital Strategies LLC lifted its position in Teleflex by 29,025.0% during the second quarter. Archford Capital Strategies LLC now owns 1,165 shares of the medical technology company’s stock valued at $217,000 after acquiring an additional 1,161 shares during the last quarter. Finally, Coldstream Capital Management Inc. purchased a new stake in Teleflex during the third quarter valued at approximately $226,000. 88.86% of the stock is owned by hedge funds and other institutional investors.
Shares of Teleflex (NYSE TFX) traded down $0.25 during trading hours on Friday, reaching $272.11. 59,113 shares of the company traded hands, compared to its average volume of 277,670. The company has a market cap of $12,269.62, a P/E ratio of 33.67, a price-to-earnings-growth ratio of 2.01 and a beta of 1.15. Teleflex has a one year low of $169.15 and a one year high of $288.78. The company has a debt-to-equity ratio of 0.88, a current ratio of 4.72 and a quick ratio of 3.70.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.